Article By:
BioMedReports
Friday, January 16, 2015 3:44 AM EDT
Depomed Inc. announced it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion.
In this article: DEPO, AMGN, DDD, ADXS, ALDX, AMBS, AMED, BSDM, BMRN, CBMG, DVCR, GALE, GB, HTBX, HEB, ISRG, OMED, PMCB, PRGB, RGDX, TGTX, WCUI